Evidence base and strategies for successful smoking cessation

Journal of Vascular Surgery

Volumn 51, Issue 6, 2010, Pages 1529-1537

  Black III, James H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CLONIDINE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; PLACEBO; VARENICLINE;

ABNORMAL DREAMING; ARTERY DISEASE; ATHEROSCLEROSIS; AWARENESS; CIGARETTE SMOKING; CLINICAL TRIAL; COUNSELING; DEATH; ECONOMIC ASPECT; EVIDENCE BASED PRACTICE; HEADACHE; HUMAN; INSOMNIA; MEDICAL CARE; MEDICAL SPECIALIST; MORNING DOSAGE; MOUTH DISEASE; NAUSEA; NEOPLASM; NOSE IRRITATION; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PRODUCTIVITY; RELAPSE; REVIEW; SKIN IRRITATION; SLEEP DISORDER; SMOKING CESSATION; SMOKING CESSATION PROGRAM; SURGEON; TOBACCO DEPENDENCE; XEROSTOMIA;

AORTIC ANEURYSM, ABDOMINAL; COUNSELING; EVIDENCE-BASED MEDICINE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; NICOTINIC AGONISTS; PATIENT EDUCATION AS TOPIC; PERIPHERAL VASCULAR DISEASES; PREOPERATIVE CARE; RISK ASSESSMENT; RISK FACTORS; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 77952236563     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.10.124     Document Type: Review

References (85)

1. Mokdad A.H., Marks J.S., Stroup J.S., and Geberding J.L. Actual causes of death on the United States, 2000. JAMA 291 (2004) 1238-1245
2. Ezzati M., and Lopez A.D. Estimates of global mortality attributable to smoking in 2000. Lancet 362 (2003) 847-852
3. Schroeder S.A. Tobacco control in the wake of the 1998 Master Settlement Agreement. N Engl J Med 350 (2004) 293-301
4. IDEM. What to do with the patient who smokes?. JAMA 294 (2005) 482-487
5. Warner K.E. Tobacco policy research: insights and contributions to public health policy. In: Warner K.E. (Ed). Tobacco control policy (2006), Jossey-Bass, San Francisco 3-86
6. Prevalence of current cigarette smoking among adults and changes in prevalence of current and day smoking - United States, 1996-2001. MMWR Morb Mortal Wkly Rep 50 (2001) 1103
7. Tobacco information and prevention source (TIPS). Atlanta: Centers for Disease Control and Prevention. http://www.cdc.gov/tobacco/data_statistics/mmwrs/by_topic/global.htm Accessed February, 2009
8. Fiore M.C., Tobacco Use and Dependence Clinical Practice and Guideline Panel, Staff, and and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service Report. JAMA 283 (2000) 3244-3254
9. Schroeder S.A. We can do better - improving the health of the American people. NEJM 357 (2007) 1221-1228
10. Erb W. Klinische beitrage zur pathologie des intermittierden hinkens. Munch Med Wochensour 2 (1911) 2487
11. Kannel W.B., and McGee D.L. Update on some epidemiological features of intermittent claudication. J Am Geriar Soc 33 (1985) 13-18
12. Murabito J.M., D'Agostino R.B., Silbershatz H., and Wilson W.F. Intermittent claudication: an update from the Framingham Heart Study. Circulation 96 (1997) 44-49
13. Reunanen A., Takkunen H., and Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 211 (1982) 249-6
14. Balkbau B., Vray M., and Eschwege E. Epidemiology of peripheral arterial disease. J Cardiovasc Pharmacol 23 (1994) S8-S16
15. Fowkes G.R., Housley E., Riemersma R.A., McIntyre C.A., Cawood E.H., Prescott R.J., et al. Smoking, lipids, glucose intolerance and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 135 (1992) 331-340
16. Kannel W.B., and Shurtleff D. The Framingham Study: cigarettes and the development of intermittent claudication. Geriatrics 28 (1973) 61-68
17. Bainton D., Sweetman P., Baker I., and Elwood P. Peripheral arterial disease: consequences for survival and association with risk factors in the Speedwell prospective heart disease study. Br Heart J 72 (1994) 128-132
18. Dagenis G.R., Maurice S., Robatille N.M., Gingras S., and Lupien P.J. Intermittent claudication in Quebec men from 1974-1986: the Quebec Cardiovascular Study. Clin Invest med 14 (1991) 93-100
19. Powell J.T., Edwards R.J., Worrell P.C., Franks P.J., Greenhalgh R.M., and Porter N.R. Risk factors associated with the development of peripheral arterial disease in smokers: a case control study. Atherosclerosis 129 (1997) 41-48
20. Quick C.R.G., and Cotton L.T. The measured effect of stopping smoking on intermittent claudication. Br J Surg 69 (1982) S24-S26
21. Willigendael E.M., Tejink J.A., Bartelink M.L., Peters R.J., Buller H.R., and Prins M.H. Smoking and patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg 41 (2005) 67-74
22. Hirsch A.T., Treat-Jacobsen D., Lando H.A., and Hatsukami D.K. The role of tobacco cessation, antiplatelet and lipid lowering therapies in the treatment of peripheral arterial disease. Vasc Med 2 (1997) 243-251
23. Olin J.W. Thromboangiitis obliterans (Buerger's disease). N Engl J Med 343 (2000) 864-869
24. Baxter B.T., Terrin M.C., and Dalman R.L. Medical management of small abdominal aortic aneurysms. Circulation 117 (2008) 1883-1889
25. Powell J.T., Worell P., MacSweeney S.T., Franks P.J., and Greenhalgh R.M. Smoking as a risk factor for abdominal aortic aneurysm. Ann NY Acad Sci 800 (1996) 246-248
26. Lederle F.A., Nelson D.B., and Joseph A.M. Smoker's relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. J Vasc Surg 38 (2003) 329-334
27. United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 346 (2002) 1445-1452
28. Bluman L.G., Mosca L., Newman N., and Simon D.G. Perioperative smoking habits and postoperative smoking complications. Chest 113 (1998) 883-889
29. Moller A.M., Maaloe R., and Pedersen T. Postoperative intensive care admittance: the role of tobacco smoking. Acta Anaesthesiol Scand 45 (2001) 345-348
30. Warner M.A., Offord K.P., Warner M.E., Lennon R.L., Conover M.A., and Jansson-Schumacher U. Role of perioperative cessation of smoking and other risk factors in postoperative pulmonary complications: a blinded prospective study of coronary artery bypass patients. Mayo Clin Proc 64 (1989) 609-616
31. Nakagawa M., Tanaka H., Tsukuma H., and Kishi Y. Relationship between the duration of the preoperative smoke-free period and the incidence of postoperative pulmonary complications after pulmonary surgery. Chest 120 (2001) 705-710
32. Zhu S.H., Melcer T., Sun J., Rosbrook B., and Pierce J.P. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 18 (2000) 305-311
33. Diagnostic and statistical manual of mental disorders, 4th ed, DSM-IV (1994), American Psychiatric Association, Washington DC text revised 2000
34. Glynn T.J., Manley M.W., and Pechacek T.F. Physician initiated smoking cessation program: the National Cancer Institute Trials. Prog Clin Biol Res 339 (1990) 11-25
35. Colby S.M., Monti P.M., Barnett N.P., Rohsenow D.J., Weisman K., Spirito A., et al. Brief motivational interviewing in a hospital setting for adolescent smoking: a preliminary study. J Consult Clin Psychol 66 (1998) 574-578
36. Recommendations regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. Am J Prev Med 20 (2001) S5-S10
37. Smith S.S., Beckley T., and Fiore M.C. Health care provider use of guideline-based smoking interventions: results from the 2003 Wisconsin Tobacco Survey. WMJ 104 (2005) 28-31
38. Rundmo T., Smedslund G., and Gotestam K.G. Motivation for smoking cessation among Norwegian public. Addict Behav 22 (1997) 377-386
39. Prochaska J.O., and Goldstein M.G. Processes of smoking cessation: implications for clinicians. Clin Chest Med 12 (1991) 727-735
40. Westman E.C., Behm F.M., Simel D.L., and Rose J.E. Smoking behavior on the first day of a quit attempt predicts long-term abstinence. Arch Intern Med 157 (1997) 335-340
41. Kenford SL, Fore MC, Jorenby DE, Smith SS, Weter D, Baker TB. Predicting smoking cessation: who will quit with and without the nicotine patch. JAMA 1194:271:589-94.
42. Brandon T.H., Tiffany S.T., Obremski K.M., and Baker T.B. Postcessation cigarette use: the process of relapse. Addict Behav 15 (1990) 105-114
43. Rigotti N.A. Treatment options for the weight-conscious smoker. Arch Intern Med 159 (1999) 1169-1171
44. Williamson D.F., Madans J., Anda R.F., Kleinman J.C., Gravino G.A., and Byers T. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 324 (1991) 739-745
45. Benowitz N.L., and Gourlay S.G. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Card 29 (1997) 1422-1431
46. Leischlow S.J., Sachs D.P.L., Bostrom A.G., and Hansen M.D. Effects of differing nicotine replacement doses on weight gain after smoking cessation. Arch Fam Med 1 (1992) 233-237
47. Nides M., Rand C., Dolce J., Murray R., O'Hara P., Voelker H., et al. Weight gain as a function of smoking cessation and 2mg nicotine gum use among middle-aged smokers with mild lung impairment in the first 2 years of the Lung Health Study. Health Psychol 13 (1994) 354-361
48. Rigotti N.A. Treatment of tobacco use and dependence. N Engl J Med 346 (2002) 502-512
49. Lancaster T., Stead L., Silagy C., and Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ 321 (2000) 355-358
50. Garrett B.E., Rose C.A., and Hennigfield J.E. Tobacco addiction and pharmacological interventions. Exper Opin Pharmacother 10 (2001) 1545-1555
51. Hennigfield J.E. Nicotine medications for smoking cessation. N Engl J Med 333 (1995) 1196-1203
52. Edwards N.B., Murphy J.K., Downs A.D., Ackerman B.J., and Rosenthal T.H. Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am J Psychiatry 146 (1989) 373-376
53. Benowitz N.L., and Jacob III P. Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 35 (1984) 499-504
54. Bohadana A., Nilsson F., Rasmussen T., and Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Int Med 160 (2000) 3128-3134
55. Joseph A.M., Norman S.M., Ferry L.H., Prochazka A.V., Westman E.C., Steele B.G., et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 335 (1996) 1792-1798
56. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Int Med 154 (1994) 989-995
57. Hajek P., West R., Foulds J., Nilsson F., Burrows S., and Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Int Med 159 (1999) 2033-2038
58. Schauffler H.H. Defining the benefits and payment for smoking cessation treatments. Tob Control 6 Suppl 1 (1997) S81-S85
59. Curry S.J., Grothaus L.C., McAfee T., and Pabiniak C. Use and cost effectiveness of smoking cessation services under four insurance plans in a health maintenance organization. N Engl J Med 339 (1998) 673-679
60. Pierce J.P., and Gilpin E.A. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 288 (2002) 1260-1264
61. Hughes J.R., Goldstein M.G., Hurt R.D., and Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 281 (1989) 72-76
62. Shiffman S., Johnston J.A., Khayrallah M., Elash C.A., Gwaltney C.J., Paty J.A., et al. The effect of bupropion on nicotine craving and withdrawal. Psychopharm 148 (2000) 33-40
63. US Department of Health and Human Services. Reducing tobacco use: a report from the Surgeon General (2000), US Department of Health and Human Services, Atlanta, GA
64. Hurt R.D., Sachs D.P.L., Glover E.D., Glover E.D., Offord K.P., Johnston A., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. NEJM 337 (1997) 1195-1202
65. Jorenby D.E., Leischlow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340 (1999) 685-691
66. Ahluwalia J.S., Harris K.J., Catley D., Okuyemi K.S., and Mayo M.S. Sustained release bupropion for smoking cessation in African Americans. JAMA 288 (2002) 468-474
67. Tapper A.R., McKinney S.L., Nashmi E., Schwarz J., Deshpende P., Labarca C., et al. Nicotine activation of alpha 4 receptors: sufficient for reward, tolerance, and sensitization. Science 306 (2004) 1029-1032
68. Mukhin A.G., Kimes A.S., Chefer S.I., Matochik J.A., Contoreggi C.S., Horti A.G., et al. Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. JNM 49 (2008) 1628-1635
69. Obach R.S., Reed-hagen A.E., Kreuger S.S., Obach B.J., O'Connell T.N., Zandi K.S., et al. Metabolism and deposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispo 34 (2006) 121-130
70. Brody A.L., Mandelkern M.A., London E.D., Olmstead R.E., Farahi J., Scheibal D., et al. Arch Gen Psych 63 (2006) 903-914
71. Jorenby J.E., Hays J.T., Rigotti N.A., Azoulay A., Watsky E.J., Williams K.E., et al., Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 56-63
72. US Food and Drug Administration. Public health advisory: important information on Chantix (varenicline). US Food and Drug Administration, Center for Drug Evaluation and Research (February 1, 2008)
73. The Institute for Safe Medication Practices. Strong safety signal seen for varenicline risks. E-Published May 21, 2008.
74. Law M., and Tang J.L. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 155 (1995) 1933-1941
75. Dornelas E.A., Sampson R.A., Gray J.F., waters D., and Thompson P.D. A randomized controlled trial of smoking cessation counseling after myocardial infarction. Prev Med 30 (2000) 261-268
76. Quist-Paulsen P., and Gallefoss F. Randomized controlled trial of smoking cessation intervention after admission for coronary heart disease. BMJ 327 (2003) 1254-1257
77. Anda R.F., Williamson D.F., Escobedo L.G., Mast E.E., Giovino G.A., and Remington P.L. Depression and the dynamics of smoking: a national perspective. JAMA 264 (1990) 1541-1545
78. Zeigelstein R.C. Depression in patients recovering from a myocardial infarction. JAMA 286 (2001) 1621-1626
79. Kronish I.M., Rieckmann H., Halm E.A., Shimbo D., Vorchheimer D., Haas D.C., et al. Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Int Med 21 (2006) 1178-1183
80. Thorndike A.N., Regan S., McKool K., Pasternak R.C., Swartz S., Torres-Finnerty N., et al. Depressive symptoms and smoking cessation after hospitalization for cardiovascular disease. Arch Int Med 168 (2008) 186-191
81. Critchley J.A., and Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 290 (2003) 86-97
82. Kenfield S.A., Stampfer M.J., Rosner B.A., and Colditz G.A. Smoking and smoking cessation in relation to mortality in women. JAMA 299 (2008) 2037-2047
83. Pignone M., Phillips C., and Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: a meta-analysis of randomized trials. BMJ 321 (2000) 983-986
84. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
85. Flather M.D., Yusuf S., Kober L., Pfeffer M., Hall A., Murray G., et al. Long-term ACE-inhibitor therapy in patients with heart failure of left ventricular dysfunction: a systematic overview of data from individual patients: ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355 (2000) 1575-1581